Back to resultsReshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription
Primary Purpose
Mild Cognitive Impairment
Status
Recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Aerobic Training
Resistance Training
Balance and Tone Training
Balance and Tone Training
Sponsored by
About this trial
This is an interventional treatment trial for Mild Cognitive Impairment
Eligibility Criteria
Inclusion Criteria:
- Community-dwelling in Metro Vancouver
- Have subjective memory complaints, defined as the self-reported feeling of memory worsening with an onset within the last 5 years, as determined by interview and corroborated by an informant
- Have a baseline Montreal Cognitive Assessment (MoCA) score < 26/30
- Mini-Mental State Examination (MMSE) score = or > 22 at screening
- Read, write, and speak English
- Not expected to start or are stable on a fixed dose of anti-dementia medications (e.g., donepezil, galantamine, etc.) during the 6-month intervention period
- Able to walk independently
- Must be in sufficient health to participate in the exercise programs
- Able to comply with scheduled visits, treatment plan, and other trial procedures
- Provide a personally signed and dated informed consent document indicating that the individual (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. In addition, an assent form will be provided at baseline and again at regular intervals
Exclusion Criteria:
- Engaged in moderate (e.g., brisk walking) physical activity > 1 time per week, or > 60 minutes per week, in the 3 months prior to study entry
- Diagnosed with dementia of any type
- Clinically suspected to have neurodegenerative disease as the cause of mild cognitive impairment (MCI) that is not Alzheimer's Disease (AD), vascular cognitive impairment (VCI), or both (e.g., multiple sclerosis, Parkinson's disease, Huntington's disease, frontotemporal dementia)
- At high risk for cardiac complications during exercise or unable to self-regulate activity or to understand recommended activity level; 5) have clinically important peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility, as determined by his/her family physician
- Taking medications that may negatively affect cognitive function, such as anticholinergics, including agents with pronounced anticholinergic properties (e.g., amitriptyline), major tranquilizers (i.e., typical and atypical antipsychotics), and anticonvulsants (e.g., gabapentin, valproic acid)
- On any hormone therapy (estrogen, progesterone, or testosterone) in the last 24 months
- Planning to participate, or already enrolled in, a concurrent clinical drug or exercise trial
Sites / Locations
- University of British ColumbiaRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Active Comparator
Arm Label
Aerobic Training and Resistance Training (A&RT)
Aerobic Training (AT)
Resistance Training (RT)
Balance and Tone Program (CON)
Arm Description
The A&RT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form.
The AT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
The RT program will be a four-times-per week program. Twice a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
The CON program will be a four-times-per week program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
Outcomes
Primary Outcome Measures
Cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale Plus (ADAS-Plus)
Cognition
Secondary Outcome Measures
Executive functions as measured by standard neuropsychological and computerized tests
Executive functions
Cardiometabolic risk factors as measured by blood panel
Cardiometabolic risk factors
Health related quality of life as measured by the EuroQol five dimensions questionnaire (EQ-5D-5L)
Quality of life
Health related quality of life as measured by the ICE-CAP
Quality of life
Mood as measured by the Center for Epidemiologic Studies Depression Scale (CES-D)
Depressive symptoms
Brain function as measured by functional magnetic resonance imaging (fMRI)
Brain function
Brain structure as measured by structural magnetic resonance imaging
Brain structure
White matter lesion volume as measured by magnetic resonance imaging
White matter lesion
Diffusion tensor imaging as measured by magnetic resonance imaging
White matter integrity
Memory as measured by standard neuropsychological and computerized tests
Memory
Visualspatial ability as measured by standard neuropsychological and computerized tests
Visualspatial ability
Cardiorespiratory capacity as measured by treadmill test
Cardiovascular fitness
Mobility as measured by 400-m walk
Mobility
Cardiometabolic risk as measured by waist to hip ratio
Cardiometabolic risk
Cardiometabolic risk as measured by body mass index
Cardiometabolic risk
Cardiometabolic risk as measured by pulse wave velocity (arterial stiffness)
Cardiometabolic risk
Cortisol levels through saliva samples
Cortisol levels
Lower body strength as measured by the 30 sec sit-to-stand
Lower body strength
Lower body strength as measured by Biodex
Lower body strength
Upper body strength as measured by grip strength
Upper body strength
Sleep quality as measured by Motion Watch actigraphy
Sleep quality
Neurotrophic factors as measured by blood
Neurotrophic factors
Mobility as measured by Short Physical Performance Battery
Mobility
Community mobility as measured by the Life Space Questionnaire
Mobility
Body composition as measured by DXA
Body composition
Loneliness as measured by the UCLA Loneliness Scale
Loneliness
Cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale - 13 items
Cognitive function
Sedentary behaviour as measure by the Sedentary Behaviour Questionnaire
Sedentary behaviour
Risk of sleep apnea as measured by the STOP Bang Questionnaire
Sleep apnea risk
Prospective falls via Monthly Calendars
Accidental falls
Social support as measured by Social Provision Scale
Social support
Mindfulness as measured by the Mindfulness Attention Awareness Scale
Mindfulness
Memory as measured by the Everyday Memory Questionnaire
Memory
Sleep as measured by the Pittsburgh Sleep Quality Index
Sleep
Functional ability as measured by the Lawson IADL
Instrumental activities of daily living
Comorbidities as measured by the Function Comorbidity Index
Chronic conditions
Mood as measured by the State and Trait Anxiety Inventory
Mood
Social network as measured by Lubben Social Network Scale
Social network
Physical activity as measured by the CHAMP Questionnaire
Physical Activity Level
ADAS-Cog Plus
Cognitive function
Verbal memory and learning using the Rey Auditory Verbal Learning Test
Verbal memory and learning
Verbal fluency (categorial of animals and semantic using F,A,S)
Verbal functioning tests requiring retrieval
Cytokines - proteins involved in immune response, as measured by blood
Cytokines
Dual-task gait using Gaitrite
Dual-task walking
Health resource utilization (e.g., access health system services/resources)
Access health system services/resources
Physical activity level (i.e., amount of light, moderate, and vigorous) measured by Motion Watch actigraphy
Physical activity levels
Sedentary behaviour (i.e., less than = or less than1.5 mets of activity) measured by Motion Watch actigraphy
Sedentary behaviour
Quality of life measured by EQ-5D-5L
Quality of life
Wellbeing measured by ICE-CAP
Wellbeing
Full Information
NCT ID
NCT02737878
First Posted
April 11, 2016
Last Updated
January 30, 2023
Sponsor
University of British Columbia
1. Study Identification
Unique Protocol Identification Number
NCT02737878
Brief Title
Reshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription
Official Title
Reshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription: Understanding Training Type and Exploring Mechanisms
Study Type
Interventional
2. Study Status
Record Verification Date
January 2023
Overall Recruitment Status
Recruiting
Study Start Date
November 13, 2017 (Actual)
Primary Completion Date
December 2023 (Anticipated)
Study Completion Date
December 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of British Columbia
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Dementia is one of the most pressing health care issues of the 21st century. Evidence suggests that exercise enhances cognitive function in healthy older adults. Most research has focused on aerobic training (AT). Therefore, investigators aim to assess the individual effects of AT and resistance training (RT), as well as the interaction effect of combining the two types of exercise training, on cognitive function in older adults with mild cognitive impairment.
Detailed Description
Investigators will conduct a 6-month assessor-blinded randomized-controlled trial of 216 community-dwelling adults with mild cognitive impairment. Individuals will be randomized to one of four experimental groups, all which receive 6 months of exercise classes four times per week: 1) combined aerobic training and resistance training; 2) aerobic training; 3) resistance training; or 4) balance and toning exercise. There will be two measurement sessions: baseline and 6 months (end of intervention period). A 12-month followup (i.e., 18 months from baseline) measurement will be done for a sub-set of participants.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mild Cognitive Impairment
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Factorial Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
216 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Aerobic Training and Resistance Training (A&RT)
Arm Type
Experimental
Arm Description
The A&RT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form.
Arm Title
Aerobic Training (AT)
Arm Type
Experimental
Arm Description
The AT program will be a four-times-per week program. Twice a week will be aerobic training consisting of outdoor walks with certified fitness instructors. The outdoor walking program will start participants out working at 45% of their heart rate reserve, and work up to 70% of the heart rate reserve. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
Arm Title
Resistance Training (RT)
Arm Type
Experimental
Arm Description
The RT program will be a four-times-per week program. Twice a week will be resistance training in which a pressurized air system and free weights will be used to provide the training stimulus. Other key strength exercises (with free weights) will include mini-squats, mini-lunges, and lunge walks. The intensity of the training stimulus will initially be at 50% to 60% of 1 repetition maximum (RM) as determined at week two, and progress to 75% to 85% of 1-RM at a work level of 6 to 8 repetitions (2 sets) by week four. The training stimulus will be increased using the 7 RM method, when 2 sets of 6-8 repetitions are completed with proper form. The other two days per week are a balance and tone program consisting of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
Arm Title
Balance and Tone Program (CON)
Arm Type
Active Comparator
Arm Description
The CON program will be a four-times-per week program. The CON group will consist of stretching exercises, basic core-strength/kegal exercises, and relaxation techniques. Other than bodyweight, no additional loading (e.g., hand weights, resistance bands, etc.) will be applied to any of the exercises.
Intervention Type
Behavioral
Intervention Name(s)
Aerobic Training
Intervention Description
Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of wearables to monitor heart rate. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Intervention Type
Behavioral
Intervention Name(s)
Resistance Training
Intervention Description
Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of a set of resistance bands of various weights. Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Intervention Type
Behavioral
Intervention Name(s)
Balance and Tone Training
Intervention Description
Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Intervention Type
Behavioral
Intervention Name(s)
Balance and Tone Training
Intervention Description
Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
To meet the public health mandates of COVID-19, when it is necessary, training will occur at home, with the use of small equipment (e.g., pilate ball). Participants will be provided access to instructional videos either by YouTube or DVD. They will be called on a weekly basis to monitor progress and compliance.
Primary Outcome Measure Information:
Title
Cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale Plus (ADAS-Plus)
Description
Cognition
Time Frame
Baseline to 6 months
Secondary Outcome Measure Information:
Title
Executive functions as measured by standard neuropsychological and computerized tests
Description
Executive functions
Time Frame
Baseline and 6 months and 18 months
Title
Cardiometabolic risk factors as measured by blood panel
Description
Cardiometabolic risk factors
Time Frame
Baseline and 6 months
Title
Health related quality of life as measured by the EuroQol five dimensions questionnaire (EQ-5D-5L)
Description
Quality of life
Time Frame
Baseline, 3 months, 6 months, 12 months, and 18 months
Title
Health related quality of life as measured by the ICE-CAP
Description
Quality of life
Time Frame
Baseline, 3 months, 6 months, 12 months, and 18 months
Title
Mood as measured by the Center for Epidemiologic Studies Depression Scale (CES-D)
Description
Depressive symptoms
Time Frame
Baseline and 6 months
Title
Brain function as measured by functional magnetic resonance imaging (fMRI)
Description
Brain function
Time Frame
Baseline and 6 months
Title
Brain structure as measured by structural magnetic resonance imaging
Description
Brain structure
Time Frame
Baseline and 6 months
Title
White matter lesion volume as measured by magnetic resonance imaging
Description
White matter lesion
Time Frame
Baseline and 6 months
Title
Diffusion tensor imaging as measured by magnetic resonance imaging
Description
White matter integrity
Time Frame
Baseline and 6 months
Title
Memory as measured by standard neuropsychological and computerized tests
Description
Memory
Time Frame
Baseline and 6 months and 18 months
Title
Visualspatial ability as measured by standard neuropsychological and computerized tests
Description
Visualspatial ability
Time Frame
Baseline and 6 months
Title
Cardiorespiratory capacity as measured by treadmill test
Description
Cardiovascular fitness
Time Frame
Baseline and 6 months
Title
Mobility as measured by 400-m walk
Description
Mobility
Time Frame
Baseline and 6 months and 18 months
Title
Cardiometabolic risk as measured by waist to hip ratio
Description
Cardiometabolic risk
Time Frame
Baseline and 6 months and 18 months
Title
Cardiometabolic risk as measured by body mass index
Description
Cardiometabolic risk
Time Frame
Baseline and 6 months and 18 months.
Title
Cardiometabolic risk as measured by pulse wave velocity (arterial stiffness)
Description
Cardiometabolic risk
Time Frame
Baseline and 6 months
Title
Cortisol levels through saliva samples
Description
Cortisol levels
Time Frame
5 times from baseline to 6 months
Title
Lower body strength as measured by the 30 sec sit-to-stand
Description
Lower body strength
Time Frame
Baseline and 6 months and 18 months
Title
Lower body strength as measured by Biodex
Description
Lower body strength
Time Frame
Baseline and 6 months
Title
Upper body strength as measured by grip strength
Description
Upper body strength
Time Frame
Baseline and 6 months
Title
Sleep quality as measured by Motion Watch actigraphy
Description
Sleep quality
Time Frame
Baseline and 6 months
Title
Neurotrophic factors as measured by blood
Description
Neurotrophic factors
Time Frame
Baseline and 6 months
Title
Mobility as measured by Short Physical Performance Battery
Description
Mobility
Time Frame
Baseline and 6 months and 18 months
Title
Community mobility as measured by the Life Space Questionnaire
Description
Mobility
Time Frame
Baseline, 3 months, 6 months, 12 months, and 18 months
Title
Body composition as measured by DXA
Description
Body composition
Time Frame
Baseline and 6 months
Title
Loneliness as measured by the UCLA Loneliness Scale
Description
Loneliness
Time Frame
Baseline and 6 months
Title
Cognitive function as measured by Alzheimer's Disease Assessment Scale Cognitive Subscale - 13 items
Description
Cognitive function
Time Frame
Baseline and 6 months and 18 months
Title
Sedentary behaviour as measure by the Sedentary Behaviour Questionnaire
Description
Sedentary behaviour
Time Frame
Baseline, 3 months, 6 months, 12 months, and 18 months
Title
Risk of sleep apnea as measured by the STOP Bang Questionnaire
Description
Sleep apnea risk
Time Frame
Baseline and 6 months
Title
Prospective falls via Monthly Calendars
Description
Accidental falls
Time Frame
Baseline and 3 months and 6 months and monthly
Title
Social support as measured by Social Provision Scale
Description
Social support
Time Frame
Baseline and 6 months
Title
Mindfulness as measured by the Mindfulness Attention Awareness Scale
Description
Mindfulness
Time Frame
Baseline and 6 months
Title
Memory as measured by the Everyday Memory Questionnaire
Description
Memory
Time Frame
Baseline and 6 months
Title
Sleep as measured by the Pittsburgh Sleep Quality Index
Description
Sleep
Time Frame
Baseline, 6 months, 12 months, and 18 months
Title
Functional ability as measured by the Lawson IADL
Description
Instrumental activities of daily living
Time Frame
Baseline and 6 months
Title
Comorbidities as measured by the Function Comorbidity Index
Description
Chronic conditions
Time Frame
Baseline, 6 months, 12 months, and 18 months
Title
Mood as measured by the State and Trait Anxiety Inventory
Description
Mood
Time Frame
Baseline and 6 months and 18 months
Title
Social network as measured by Lubben Social Network Scale
Description
Social network
Time Frame
Baseline and 6 months
Title
Physical activity as measured by the CHAMP Questionnaire
Description
Physical Activity Level
Time Frame
Baseline and 3 months and 6 months and monthly
Title
ADAS-Cog Plus
Description
Cognitive function
Time Frame
18 months
Title
Verbal memory and learning using the Rey Auditory Verbal Learning Test
Description
Verbal memory and learning
Time Frame
Baseline, 6 months, and 18 months
Title
Verbal fluency (categorial of animals and semantic using F,A,S)
Description
Verbal functioning tests requiring retrieval
Time Frame
Baseline, 6 months, and 18 months
Title
Cytokines - proteins involved in immune response, as measured by blood
Description
Cytokines
Time Frame
Baseline and 6 months
Title
Dual-task gait using Gaitrite
Description
Dual-task walking
Time Frame
Baseline and 6 months
Title
Health resource utilization (e.g., access health system services/resources)
Description
Access health system services/resources
Time Frame
Baseline, 3 months, and 6 months
Title
Physical activity level (i.e., amount of light, moderate, and vigorous) measured by Motion Watch actigraphy
Description
Physical activity levels
Time Frame
Baseline and 6 months
Title
Sedentary behaviour (i.e., less than = or less than1.5 mets of activity) measured by Motion Watch actigraphy
Description
Sedentary behaviour
Time Frame
Baseline and 6 months
Title
Quality of life measured by EQ-5D-5L
Description
Quality of life
Time Frame
Baseline, 3 months, 6 months, and 18 months
Title
Wellbeing measured by ICE-CAP
Description
Wellbeing
Time Frame
Baseline, 3 months, 6 months, and 18 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
65 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Community-dwelling in Metro Vancouver
Have subjective memory complaints, defined as the self-reported feeling of memory worsening with an onset within the last 5 years, as determined by interview and corroborated by an informant
Have a baseline Montreal Cognitive Assessment (MoCA) score < 26/30
Mini-Mental State Examination (MMSE) score = or > 22 at screening
Read, write, and speak English
Not expected to start or are stable on a fixed dose of anti-dementia medications (e.g., donepezil, galantamine, etc.) during the 6-month intervention period
Able to walk independently
Must be in sufficient health to participate in the exercise programs
Able to comply with scheduled visits, treatment plan, and other trial procedures
Provide a personally signed and dated informed consent document indicating that the individual (or a legally acceptable representative) has been informed of all pertinent aspects of the trial. In addition, an assent form will be provided at baseline and again at regular intervals
Exclusion Criteria:
Engaged in moderate (e.g., brisk walking) physical activity > 1 time per week, or > 60 minutes per week, in the 3 months prior to study entry
Diagnosed with dementia of any type
Clinically suspected to have neurodegenerative disease as the cause of mild cognitive impairment (MCI) that is not Alzheimer's Disease (AD), vascular cognitive impairment (VCI), or both (e.g., multiple sclerosis, Parkinson's disease, Huntington's disease, frontotemporal dementia)
At high risk for cardiac complications during exercise or unable to self-regulate activity or to understand recommended activity level; 5) have clinically important peripheral neuropathy or severe musculoskeletal or joint disease that impairs mobility, as determined by his/her family physician
Taking medications that may negatively affect cognitive function, such as anticholinergics, including agents with pronounced anticholinergic properties (e.g., amitriptyline), major tranquilizers (i.e., typical and atypical antipsychotics), and anticonvulsants (e.g., gabapentin, valproic acid)
On any hormone therapy (estrogen, progesterone, or testosterone) in the last 24 months
Planning to participate, or already enrolled in, a concurrent clinical drug or exercise trial
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Nathan Wei, BSc
Phone
604-875-4111
Ext
69313
Email
cogmob.research@hiphealth.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Teresa Liu-Ambrose, PhD, PT
Phone
604-875-4111
Ext
69059
Email
teresa.ambrose@ubc.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Teresa Liu-Ambrose, PhD, PT
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
John Best, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jennifer Davis, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lara Boyd, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Liisa Galea, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Charlie Goldsmith, PhD
Organizational Affiliation
Simon Fraser University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ging-Yuek Robin Hsiung, MD, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Alexander MacKay, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Lindsay Nagamatsu, PhD
Organizational Affiliation
Western University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Claudia Jacova, PhD
Organizational Affiliation
Pacific University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Arthur Kramer, PhD
Organizational Affiliation
Northeastern University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michelle Voss, PhD
Organizational Affiliation
University of Iowa
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Cindy Barha, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Joel Singer, PhD
Organizational Affiliation
University of British Columbia
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of British Columbia
City
Vancouver
State/Province
British Columbia
ZIP/Postal Code
V5Z 1M9
Country
Canada
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nathan Wei, BSc
Phone
604-875-4111
Ext
69056
Email
cogmob.research@hiphealth.ca
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
36085237
Citation
Barha CK, Falck RS, Best JR, Nagamatsu LS, Hsiung GR, Sheel AW, Hsu CL, Kramer AF, Voss MW, Erickson KI, Davis JC, Shoemaker JK, Boyd L, Crockett RA, Ten Brinke L, Bherer L, Singer J, Galea LAM, Jacova C, Bullock A, Grant S, Liu-Ambrose T. Reshaping the path of mild cognitive impairment by refining exercise prescription: a study protocol of a randomized controlled trial to understand the "what," "for whom," and "how" of exercise to promote cognitive function. Trials. 2022 Sep 9;23(1):766. doi: 10.1186/s13063-022-06699-7.
Results Reference
derived
Learn more about this trial
Reshaping the Path of Mild Cognitive Impairment by Refining Exercise Prescription
We'll reach out to this number within 24 hrs